...
首页> 外文期刊>Molecules >Pharmacogenomic Identification of c-Myc/Max-Regulated Genes Associated with Cytotoxicity of Artesunate towards Human Colon, Ovarian and Lung Cancer Cell Lines
【24h】

Pharmacogenomic Identification of c-Myc/Max-Regulated Genes Associated with Cytotoxicity of Artesunate towards Human Colon, Ovarian and Lung Cancer Cell Lines

机译:与青蒿琥酯对人结肠,卵巢和肺癌细胞系细胞毒性相关的c-Myc / Max调控基因的药物基因组学鉴定

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Development of novel therapy strategies is one of the major pressing topics of clinical oncology to overcome drug resistance of tumors. Artesunate (ART) is an anti-malarial drug, which also exerts profound cytotoxic activity towards cancer cells. We applied a gene-hunting approach using microarray-based transcriptome-wide mRNA expression profiling and COMPARE analyses. We identified a set of genes, whose expression was associated either with high IC50 values or low IC50 values for ART. Therefore, these genes may function as resistance or sensitivity factors for response of tumor cells towards ART. This viewpoint is conceivable for genes involved in ribosomal activity, drug transport, cellular antioxidant defense, apoptosis, cell proliferation, cell cycle progression etc. An investigation of underlying signal transduction by pathway analysis suggested a role of the signaling pathways related to tumor necrosis factor (TNF) and the tumor suppressor p53. On the other hand, there were genes without obvious functional link to cellular response to ART, such as genes involved in the survival of cochlear outer and inner hair cells etc. We proved the hypothesis that ART influences the activity of transcription factors regulating downstream genes involved or not involved in response of cancer cells towards ART. This would explain the identification of genes with and without obvious relation to the cytotoxic activity of ART by microarray and COMPARE analyses. By analysis of the binding motifs for the transcription factors c-Myc and Max, we indeed found that 53 of 56 genes contained one or more binding sites for c-Myc/Max upstream of the gene-location. We conclude that c-Myc and Max-mediated transcriptional control of gene expression might contribute to the therapeutic effects of ART in cancer cells, but may also confer unwanted side effects by affecting therapy-unrelated genes.
机译:开发新的治疗策略是克服肿瘤耐药性的临床肿瘤学的主要紧迫课题之一。青蒿琥酯(ART)是一种抗疟疾药物,对癌细胞也具有深远的细胞毒活性。我们应用了基于基因芯片的转录组范围的mRNA表达谱和COMPARE分析的基因狩猎方法。我们鉴定了一组基因,这些基因的表达与ART的高IC 50 值或低IC 50 值相关。因此,这些基因可以作为肿瘤细胞对ART的应答的抗性或敏感性因子。对于涉及核糖体活性,药物转运,细胞抗氧化剂防御,细胞凋亡,细胞增殖,细胞周期进程等的基因,这种观点是可以想象的。通过途径分析对基础信号转导的研究表明,信号途径与肿瘤坏死因子有关( TNF)和抑癌剂p53。另一方面,存在与ART对细胞反应无明显功能联系的基因,例如与耳蜗内外毛细胞的存活有关的基因等。我们证明了ART影响调节涉及的下游基因的转录因子活性的假说。或不参与癌细胞对ART的反应。这将解释通过微阵列和COMPARE分析鉴定与ART的细胞毒活性没有明显关系的基因。通过分析转录因子c-Myc和Max的结合基序,我们确实发现56个基因中的53个在基因定位的上游含有一个或多个c-Myc / Max结合位点。我们得出结论,基因表达的c-Myc和Max介导的转录控制可能有助于ART在癌细胞中的治疗作用,但也可能通过影响与治疗无关的基因而带来不良副作用。

著录项

  • 来源
    《Molecules》 |2010年第4期|共25页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种
  • 中图分类 有机化学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号